Back

What value do SGLT2 inhibitors offer to patients hospitalised for heart failure?

26 August 2023 (13:00 - 13:15)
Organised by: Logo
Congress Presentation Part of: Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the hospital setting Treatment Open Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor John R Teerlink

San Francisco Veterans Affairs Medical Centre, San Francisco (United States of America)

4 More presentations in this session

Presentation thumbnail
Welcome and introduction
Professor I. Pina (Philadelphia, US)
Slides Video
Presentation thumbnail
2023 heart failure guideline recommendations: where do we stand?
Professor A. Bayes Genis (Badalona, ES)
Slides Video
Presentation thumbnail
Starting SGLT2 inhibitors in practice: considerations for implementation in the hospital setting
Doctor M. Kosiborod (Kansas City, US)
Slides Video
Presentation thumbnail
Audience questions and close
Slides Video

Access the full session

Session thumbnail
Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the hospital setting
Video

The Event

Event poster

ESC Congress 2023

26 August 2023 13:00 CET
You may be interested in
thumbnail
Congress Presentation
The SGLT2 inhibitor empagliflozin in patients hospitalised for acute heart failure: a multinational randomised trial
thumbnail
Congress Session
Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the hospital setting
thumbnail
Congress Presentation
Therapeutic role of SGLT-2 inhibitors in heart failure in the hospital - from pathophysiological mechanisms to clinical evidence

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources